Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

t investors in evaluating the results of the business and analyzing the underlying trends in our business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for, or as superior to, financial reporting measures prepared in accordance with GAAP. We have provided a reconciliation of these measures to GAAP in the attached tables.

    Conference Call Information
    ---------------------------

    A conference call to discuss these financial results will be held today,
Thursday August 6, 2009 at 8:00 AM PT (11:00 AM ET).

    Dial-in information:
    North America (toll-free): (866) 700-6067
    International: (617) 213-8834
    Enter Passcode: 91816046

    An archived replay of the call will be available until August 13, 2009.
    North America (toll-free): (888) 286-8010
    International: (617) 801-6888
    Enter Passcode: 23483326

    A live webcast will be available to all interested parties through the
Investors section of Angiotech's website: www.angiotech.com



                       ANGIOTECH PHARMACEUTICALS, INC.
                 CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                                 (Unaudited)


    (in thousands of U.S.$, except                Three months ended
     share and per share data)                      June 30, 2009
    -------------------------------------------------------------------------
                                         Reported   Adjustments     Adjusted

    REVENUE
    Royalty revenue                    $   16,996   $      -      $   16,996
    Product sales, net                     47,179          -          47,179
    License fees                              398        (398) a           -
    --------------------------------- ---------------------------------------
                                           64,573        (398)        64,175
    --------------------------------- -----------------------
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... "Global Enzyme for Pulp & Paper Industry Report 2014" ... Global Enzyme for Pulp & Paper Industry Report 2014 ... state of the global enzyme for pulp & paper ... of the industry including definitions, classifications, applications and industry ...
(Date:8/27/2014)... Florida (PRWEB) August 27, 2014 ... (SCI) is announcing the creation of the Sancilio ... to take the SCI’s philosophy of looking to ... research and development actions are based on sound ... new Scientific Advisory Board provides a vehicle for ...
(Date:8/27/2014)... College, PA (PRWEB) August 27, 2014 ... Simulation Software with new features for the biomedical ... is an enhanced Biological Thermal Sensor, exclusive to the ... a specialty version of XFdtd, developed to calculate the ... export functionality has been added to all versions to ...
(Date:8/26/2014)... ANGELES , Aug. 26, 2014  NeuroSigma, Inc., ... company established to develop bioelectronic technologies, today announced that ... with the U.S. Securities and Exchange Commission relating to ... The number of shares to be offered and the ... been determined. Jefferies LLC will act as ...
Breaking Biology Technology:Global Enzyme for Pulp & Paper Industry Report 2014 2New Sancilio & Company, Inc. Scientific Board 2New Sancilio & Company, Inc. Scientific Board 3Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 2Remcom Announces Enhanced Biological Thermal Sensor and Other Biomedical Features in XFdtd EM Simulation Software Update 3
... Sept. 23 S*BIO Pte Ltd today announced ... will support the continued development of S*BIO,s clinical ... reflects the international investment community,s strong interest in ... clinical development and the quality of our various ...
... China, Sept. 22 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, ... ), which develops, manufactures, and markets specialty pharmaceutical ... has successfully completed Phase I clinical trials of ... Cephalosporin continues to be the most widely prescribed ...
... VANCOUVER, Sept. 22 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... of results from a randomized Phase 2 trial ... results showed a survival benefit with the investigational ... cancer. The median overall survival for patients who ...
Cached Biology Technology:S*BIO Announces US$5 Million Investment by Mitsui Ventures 2S*BIO Announces US$5 Million Investment by Mitsui Ventures 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 2China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 3China Pharma Holdings, Inc. Successfully Completes Phase I Clinical Trials of New Anti-Drug-Resistance Antibiotic 4OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 2OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 3OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 4OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial 5
(Date:8/27/2014)... -- When we want to listen carefully to someone, ... second thing we do is stop moving altogether. This ... generated by our own movements. , This interplay between ... the brain. Indeed, indirect evidence has long suggested that ... the auditory cortex, which gives rise to our conscious ...
(Date:8/27/2014)... Aug. 27, 2014 /PRNewswire-iReach/ -- The IEEE Engineering in ... th Annual International Conference (EMBC,14), this year being ... Chicago, Illinois , from Tuesday, August ... leaders, students, and industry professionals in science, medicine, and ... http://photos.prnewswire.com/prnh/20140827/140333 This year,s conference ...
(Date:8/27/2014)... deadly disease that exists as five strains, none of ... strains is the Sudan ebolavirus (SUDV). Although not the ... illness, even as recently as 2012. In a new ... , researchers now report a possible therapy that could ... Dye, Sachdev Sidhu, Jonathan Lai and colleagues explain that ...
Breaking Biology News(10 mins):Stop and listen: Study shows how movement affects hearing 2Stop and listen: Study shows how movement affects hearing 3Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 2Global Leaders In Science, Medicine, And Engineering Gather For The 36th Annual International Conference Of The IEEE Engineering In Medicine And Biology Society, August 26-30 In Chicago 3Potential therapy for the Sudan strain of Ebola could help contain some future outbreaks 2
... Do you want that in a pill or a shot? ... choice. The problem with administering many medications orally is that ... site in the gastrointestinal tract where the medicine can be ... by Brown University researchers could solve the problem by safely ...
... with common blood pressure medications may cause hypotension ... older patients, requiring hospitalization, according to a study ... Association Journal ) (pre-embargo link only) http://www.cmaj.ca/embargo/cmaj100702.pdf ... are among the most widely prescribed antibiotics, with ...
... Stanford University School of Medicine, in collaboration with BioParadox, ... plasma as a promising biologic treatment for myocardial infarction ... online in Cardiovascular Revascularization Medicine and will ... Therapy for Cardiovascular Disease at Columbia University Medical Center, ...
Cached Biology News:Magnetically controlled pill could boost body's absorption of drugs 2RevaTen platelet-rich plasma shows promise as potential treatment for heart attacks 2
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
ID clarifier: With ethidium bromide (50 μg/ml)...
... in DMEM and harvested at the log phase ... antigens in their native forms, cells were fixed ... a 12-well (5 mm) adhesive coated slide, with ... attachment and to minimize background staining. Each ...
Biology Products: